Inventor · disambiguated record
Matthew D. Alexander
Also filed as: ALEXANDER MATTHEW · ALEXANDER MATTHEW D · ALEXANDER MATTHEW DAVID
32 granted patents·12 pending applications·193 citations·filing 2010–2025
97Inventor score
Top patents by PatentIndex Score
44 records- 0197US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0296US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0396US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0496US10577380B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2019·Granted Mar 3, 2020·10 cites·4 claims
- 0596US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0695US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0794US10253040B1MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2017·Granted Apr 9, 2019·12 cites·15 claims
- 0894US9458175B2MK2 inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Granted Oct 4, 2016·16 cites·32 claims
- 0993US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 1093US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 1193US9790235B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2016·Granted Oct 17, 2017·12 cites·18 claims
- 1291US8415486B2IAP inhibitorsCONDON STEPHEN M·Filed 2010·Granted Apr 9, 2013·23 cites·33 claims
- 1390US10227325B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2018·Granted Mar 12, 2019·6 cites·18 claims
- 1489US10138256B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2014·Granted Nov 27, 2018·11 cites·12 claims
- 1588US10398700B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 1688US9938254B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2017·Granted Apr 10, 2018·5 cites·33 claims
- 1787US10149849B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Dec 11, 2018·2 cites·3 claims
- 1886US8481495B2IAP inhibitorsCONDON STEPHEN M·Filed 2010·Granted Jul 9, 2013·9 cites·28 claims
- 1985US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 2084US11584757B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2020·Granted Feb 21, 2023·1 cites·20 claims
- 2184US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 2284US2023158035A1Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2023·Application pending·0 cites
- 2382US11358952B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Jun 14, 2022·1 cites·21 claims
- 2482US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 2580US2024217955A1Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 2678US10618883B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2019·Granted Apr 14, 2020·1 cites·15 claims
- 2778US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 2877US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 2977US11945804B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Apr 2, 2024·0 cites·23 claims
- 3076US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 3175US11590139B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2021·Granted Feb 28, 2023·0 cites·52 claims
- 3272US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 3372US2025320183A1Modulators of BCL6 as Ligand Directed DegradersCELGENE CORP·Filed 2025·Application pending·0 cites
- 3469US11365184B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2020·Granted Jun 21, 2022·0 cites·12 claims
- 3569US10675281B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Jun 9, 2020·0 cites·20 claims
- 3668US12404239B2Modulators of BCL6 as ligand directed degradersCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·10 claims
- 3764US2025282771A1Tetrahydroisoquinoline heterobifunctional bcl-xl degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3864US2025288683A1Tetrahydroisoquinoline heterobifunctional bcl-xl degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3963US2024238423A9Tetrahydroisoquinoline heterobifunctional bcl-xl degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4061US2025100995A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 4160US11098061B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2018·Granted Aug 24, 2021·0 cites·14 claims
- 4259US2024368118A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 4359US2024374591A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 4450US2013274278A1Iap inhibitorsTETRALOGIC PHARM CORP·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew D. Alexander files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →